Azitra AZTR

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    +$0.01 (+2.15%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of Azitra (AZTR)
    Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $0.35

    • Market Cap

      $5.24 Million

    • Price-Earnings Ratio

      -0.15

    • Total Outstanding Shares

      14.98 Million Shares

    • Total Employees

      12

    • Dividend

      No dividend

    • IPO Date

      June 16, 2023

    • SIC Description

      Pharmaceutical Preparations

    • Primary Exchange

      American Stock Exchange

    • Type

      Common Stock

    • Headquarters

      21 business park drive, suite 6, Branford, CT, 06405

    • Homepage

      https://www.azitrainc.com

    Historical Stock Splits

    If you bought 30 shares of AZTR before July 1, 2024, you'd have 1 share today.
    Execution DateSplit Amount
    July 1, 20241-for-30 (Reverse Split)

    Cash Flow Statement

    January 1, 2024 to December 31, 2024
    MetricValue
    Net Cash Flow From Investing Activities, Continuing$-379,246
    Net Cash Flow From Operating Activities, Continuing$-10.18 Million
    Net Cash Flow, Continuing$2.76 Million
    Net Cash Flow From Financing Activities$13.32 Million
    Net Cash Flow From Operating Activities$-10.18 Million
    Net Cash Flow From Financing Activities, Continuing$13.32 Million

    Income Statement

    January 1, 2024 to December 31, 2024
    MetricValue
    Operating Income/Loss$-10.99 Million
    Income Tax Expense/Benefit, Current$9,031
    Other Operating Expenses$6.27 Million
    Net Income/Loss Attributable To Parent$-8.97 Million
    Income Tax Expense/Benefit, Deferred$0
    Preferred Stock Dividends And Other Adjustments$0

    Comprehensive Income

    January 1, 2024 to December 31, 2024
    MetricValue
    Other Comprehensive Income/Loss$0
    Comprehensive Income/Loss$-8.97 Million
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
    Comprehensive Income/Loss Attributable To Parent$-8.97 Million

    Balance Sheet

    January 1, 2024 to December 31, 2024
    MetricValue
    Equity Attributable To Noncontrolling Interest$0
    Equity Attributable To Parent$5.70 Million
    Equity$5.70 Million
    Intangible Assets$246,420
    Noncurrent Liabilities$284,647
    Other Current Assets$4.66 Million

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about AZTR from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      ⓒ 2025 Financhle. All Rights Reserved.